TrialBritish journal of cancer2008

A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study).

J Stebbing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.